Cytotoxic Drugs Articles & Analysis
23 articles found
Antibody-Drug Conjugates (ADCs) represent a groundbreaking advancement in targeted cancer therapy, combining the specificity of antibodies with the potency of cytotoxic drugs. ...
Among the most promising strategies in this endeavor are the use of tumor models for breast cancer and the development of customized antibody-drug conjugates (ADCs). These advancements not only enhance our understanding of the disease but also pave the way for more targeted therapeutic solutions. ...
ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic or radioactive compound. They combine the specificity of antibodies, which enables specific target cell binding, and the cell-killing activity of cytotoxic drugs, providing a method of delivering these agents directly to cancer cells. ...
With the approval of many antibody-drug conjugation (ADC) drugs around the world since 2019, conjugate drugs have developed into one of the hottest tracks in the pharmaceutical industry. ...
In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the therapeutic index while providing selective delivery. ...
Biopharma PEG, a leading innovator in polyethylene glycol (PEG) derivatives, proudly introduces its featured Azide PEG series, which can be used in drug development, click chemistry, ADCs (Antibody Drug Conjugates), PROTACs (Proteolysis Targeting Chimeras), and beyond. ...
Antibody drug conjugates (ADCs) are a new class of biopharmaceuticals that use monoclonal antibodies to target tumor cells to deliver potent cytotoxic drugs. ...
Average drug-to-antibody ratio (DAR) and drug load distribution are two vital properties of antibody drug conjugates (ADCs). ...
Improve ADC production In recent years, scientists have developed a new class of targeted drugs - antibody-drug conjugate (ADC). In the first generation of ADCs, the traditional coupling reaction is used, and it is not possible to control how many cytotoxic drug molecules bind to amino acid residues in monoclonal antibodies, nor ...
They combine the high specificity of monoclonal antibody drugs with the high activity of small molecule cytotoxic drugs, which can improve the targeting of antitumor drugs and reduce the probability of toxic and side effects. ...
Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. ...
Drug-to-antibody ratio (DAR, drug-to-antibody ratio) The number of cytotoxic drugs connected to each antibody is the drug-to-antibody ratio (DAR). When the DAR increases, the drug metabolism rate of ADC drugs increases, the half-life decreases, and the systemic toxicity ...
Dertrastuzumab is an antibody-drug conjugate (ADC) drug consisting of a humanized monoclonal antibody targeting HER2 attached to a topoisomerase 1 inhibitor payload via a tetrapeptide cleavable linker. ...
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). ...
Antibody-drug conjugates (ADCs) usually consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs via chemical linkers. ...
Alucent Biomedical Inc. is rethinking peripheral artery disease (PAD) treatment with a novel natural scaffolding technology based on a light-activated drug therapy delivered via a balloon catheter. This first-of-its-kind drug-device therapy, known as Natural Vascular Scaffolding (AlucentNVS), is designed to provide a more natural and effective way of establishing ...
There are three types of human infection: the first type of mild infection can be eliminated by the body through an effective immune response without clinical symptoms; the second type is due to chronic persistent self-infection with intermittent gastrointestinal symptoms; the third type Disseminated severe infections can occur in patients with long-term use of immunosuppressants, ...
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. For this purpose, PBD dimers have been developed, which have a molecular structure containing two alkylated imine functional groups capable of forming covalent bonds with ...
Antibody-drug conjugate (ADC), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. ...
Adcetris, Polivy, and second-generation cleavable linkers Meanwhile, Seagen (formerly Seattle Genetics) designed its own coupling technology to bioconjugate marigold (MMAE) to the cysteine residues of anti-CD30 antibodies via the cleavable linker mc-VC-PABC, which contains a maleimide-based spacer, a standard Val Cit dipeptide sequence as a histoproteinase substrate, and a PABC self-degrading ...